Are monoclonal antibodies a solution for prolonged COVID symptoms? Recent research published in the American Journal of Emergency Medicine unveils a promising avenue for alleviating long COVID symptoms through the use of monoclonal antibodies. This study, focusing on three individuals in Florida, showcases notable recoveries following the administration of the casirivimab/imdevimab (Regeneron) monoclonal antibody cocktail, providing a glimmer of hope for the millions grappling with persistent post-COVID complications.
Regeneron
Dr. Paul Pepe, a coauthor of the study and professor at the University of Texas Health Sciences Center, expressed surprise at the swift and comprehensive improvements observed in the patients. Regardless of the duration of their long COVID experience, significant progress was noted within a mere 5 days of receiving the Regeneron treatment.
The three patients, initially infected with COVID-19 in 2020 or the first half of 2021, received Regeneron either after reinfection or as a preventive measure. The infusions aimed to impede the progression of long-term COVID, addressing symptoms such as physical fatigue, exercise intolerance, chest pain, heart palpitations, shortness of breath, cognitive fatigue, and memory problems.
Monoclonal Antibodies Treatment
The study found a substantial and often complete disappearance of symptoms across the board, a sentiment echoed by reports from family members. A 63-year-old woman, one of the patients, experienced a profound turnaround after her monoclonal antibody treatment. Opting for Regeneron as a preventative measure after exposure to COVID-19 in October 2021, she witnessed a rapid alleviation of debilitating symptoms, including intense chest pain and cognitive impairment, enabling her to resume normal activities.
Researchers posit various theories regarding the mechanisms behind monoclonal antibodies' success in treating long COVID. Dr. Aileen Marty suggests that the antibodies may prompt the body to eliminate residual virus, especially in cases where conventional testing fails to detect low viral levels. Another theory proposes that monoclonal antibodies displace dysfunctional antibodies responsible for attacking the body's cells, offering relief from long COVID symptoms.
While the study underscores the efficacy of Regeneron in the cases observed, researchers acknowledge the imperative for further investigation, particularly concerning newer COVID-19 strains like Omicron. Future plans include establishing a registry of volunteer patients with severe long COVID to evaluate responses to different monoclonal antibodies.
Despite ongoing research, the three patients who responded positively to Regeneron have reclaimed their pre-COVID lives, marking a significant advancement in the treatment of long COVID and instilling hope in individuals and families who have endured the profound impact of this condition.
About Orlando Medical News
Orlando Medical News is the number one news source for medical-related content in Central Florida. Through twenty years of service, we’ve cultivated a strong audience of dedicated healthcare professionals. Orlando Medical News is your source for the best medical news in Central Florida and your trusted advertising platform which reaches far into the medical community of Central Florida healthcare professionals.
